Skip to content
naulon

Not checkedNot checked for notices yet.

Analyses of the toxic properties of recombinant human Cyclophilin A in mice

Anastasiya Kalinina, Mariya Zamkova, Elena Antoshina and 4 more

Journal of Immunotoxicology · 2019

doi:10.1080/1547691x.2019.1665597 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Cyclophilin A (CypA), an 18 kDa multi-functional protein with cis–trans isomerase activity, is both a ligand for cyclosporine A and a proinflammatory factor. CypA is also a chemoattractant for hemopoietic stem cells and progenitors of different lineages, and can mediate regenerative processes in an organism. Accumulated experimental data have suggested there are practical applications for this protein in the treatment of several diseases (i.e. neutralization of cyclosporine A side effects, etc.). However, the range of CypA safe doses as well as its toxic effects remain unknown. The study here investigated the acute toxicity of a single intraperitoneal (IP) or subcutaneous (SC) dosing of recombinant human CypA (rhCypA) in both female and male mice and its effect on gene expression of acute phase proteins (APP) in the female mice after IP treatment. The results showed that toxicity of rhCypA was most evident in female and male mice dosed IP with 750 mg/kg, and manifested as kidney injury and increased granulocyte/lymphocyte ratios in the blood. Enhanced expression of Sаа1 and Sаа2 genes was induced with doses of 0.1–2 mg/mouse of rhCypA. Injection of the maximal dose (750 mg/kg) significantly stimulated expression of all the APP genes studied.

Abstract licence: CC BY-NC

References41

  1. 13.

39 more references, whose wording the paper’s licence keeps private.

All 41 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.